167 related articles for article (PubMed ID: 38573819)
21. ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas.
Wang W; Friedland SC; Guo B; O'Dell MR; Alexander WB; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Myers JR; Ashton JM; Dunne RF; Steiner LA; Hezel AF
Gut; 2019 Jul; 68(7):1245-1258. PubMed ID: 30228219
[TBL] [Abstract][Full Text] [Related]
22. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.
Grabner B; Schramek D; Mueller KM; Moll HP; Svinka J; Hoffmann T; Bauer E; Blaas L; Hruschka N; Zboray K; Stiedl P; Nivarthi H; Bogner E; Gruber W; Mohr T; Zwick RH; Kenner L; Poli V; Aberger F; Stoiber D; Egger G; Esterbauer H; Zuber J; Moriggl R; Eferl R; Győrffy B; Penninger JM; Popper H; Casanova E
Nat Commun; 2015 Mar; 6():6285. PubMed ID: 25734337
[TBL] [Abstract][Full Text] [Related]
23. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
24. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T; Catapano CV
Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
[TBL] [Abstract][Full Text] [Related]
25. Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells.
Zhao C; Yang L; Zhou F; Yu Y; Du X; Xiang Y; Li C; Huang X; Xie C; Liu Z; Lin J; Wang L; Liang G; Cui R
Oncogene; 2020 May; 39(20):3997-4013. PubMed ID: 32242147
[TBL] [Abstract][Full Text] [Related]
26. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
[TBL] [Abstract][Full Text] [Related]
27. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
28. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
[TBL] [Abstract][Full Text] [Related]
29. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
30. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer.
Zhong X; Zheng L; Shen J; Zhang D; Xiong M; Zhang Y; He X; Tanyi JL; Yang F; Montone KT; Chen X; Xu C; Xiang AP; Huang Q; Xu X; Zhang L
Mol Cell Biol; 2016 Nov; 36(21):2742-2754. PubMed ID: 27550813
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.
Schofield HK; Zeller J; Espinoza C; Halbrook CJ; Del Vecchio A; Magnuson B; Fabo T; Cali Daylan AE; Kovalenko I; Lee HJ; Yan W; Feng Y; Karim SA; Kremer DM; Kumar-Sinha C; Lyssiotis CA; Ljungman M; Morton JP; Galbán S; Fearon ER; Pasca di Magliano M
JCI Insight; 2018 Jan; 3(2):. PubMed ID: 29367463
[TBL] [Abstract][Full Text] [Related]
32. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3.
Zhu L; Qin H; Li PY; Xu SN; Pang HF; Zhao HZ; Li DM; Zhao Q
J Exp Clin Cancer Res; 2012 Mar; 31(1):29. PubMed ID: 22458379
[TBL] [Abstract][Full Text] [Related]
33. A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition.
McFaline-Figueroa JL; Hill AJ; Qiu X; Jackson D; Shendure J; Trapnell C
Nat Genet; 2019 Sep; 51(9):1389-1398. PubMed ID: 31477929
[TBL] [Abstract][Full Text] [Related]
34. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
[TBL] [Abstract][Full Text] [Related]
35. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
[TBL] [Abstract][Full Text] [Related]
36. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
[TBL] [Abstract][Full Text] [Related]
37. KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis.
Yoon C; Till J; Cho SJ; Chang KK; Lin JX; Huang CM; Ryeom S; Yoon SS
Mol Cancer Res; 2019 Sep; 17(9):1945-1957. PubMed ID: 31217166
[TBL] [Abstract][Full Text] [Related]
38. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.
Collins MA; Bednar F; Zhang Y; Brisset JC; Galbán S; Galbán CJ; Rakshit S; Flannagan KS; Adsay NV; Pasca di Magliano M
J Clin Invest; 2012 Feb; 122(2):639-53. PubMed ID: 22232209
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.
Schneeweis C; Wirth M; Saur D; Reichert M; Schneider G
Small GTPases; 2018 Nov; 9(6):457-464. PubMed ID: 27880072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
